Risankizumab 360mg/2.4ml solution for injection cartridges
NHS hospitals in England used £109,752,655 of indicative cost of Risankizumab 360mg/2.4ml solution for injection cartridges in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is up 98.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Risankizumab 360mg/2.4ml solution for injection cartridges: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Risankizumab 360mg/2.4ml solution for injection cartridges most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Barts Health Nhs Trust | £4,856,091 |
| Guy's & St Thomas' Nhs Foundation Trust | £4,200,852 |
| London North West Healthcare Nhs Trust | £4,194,199 |
| Salford Royal Nhs Foundation Trust | £4,187,547 |
| University College London Foundation Tr | £3,911,482 |
| St George's Univ Hosps Foundation Nhst | £3,811,699 |
| Oxford University Hospitals Nhs Ft | £3,505,699 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £3,106,568 |
| Gloucestershire Hpls Nhs Foundation Trst | £2,557,763 |
| Western Sussex Hospitals Nhs Found Trust | £2,457,981 |
The primary-care picture
Risankizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Risankizumab medicine page.